The current financial score of Orchestra Biomed Holdings Inc is 5.02. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 88.00K, representing a year-over-year decrease of 89.47%, while its net profit experienced a year-over-year decrease of 24.36%.
The current valuation score of Orchestra Biomed Holdings Inc is 7.70. Its current P/E ratio is -6.28, which is -79.54% below the recent high of -1.28 and -163.57% above the recent low of -16.54.
The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00. The average price target is 12.14, with a high of 20.00 and a low of 9.00.
The current price momentum score of Orchestra Biomed Holdings Inc is 5.24. Currently, the stock price is trading between the resistance level at 6.72 and the support level at 4.95, making it suitable for range-bound swing trading.
The current institutional shareholding score of Orchestra Biomed Holdings Inc is 3.00. The latest institutional shareholding proportion is 42.19%, representing a quarter-over-quarter increase of 7.86%.
The current risk assessment score of Orchestra Biomed Holdings Inc is 3.99. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.